Stock Traders Buy High Volume of Maravai LifeSciences Call Options (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the recipient of some unusual options trading on Wednesday. Stock investors purchased 5,247 call options on the stock. This represents an increase of approximately 964% compared to the average daily volume of 493 call options.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on MRVI shares. The Goldman Sachs Group cut shares of Maravai LifeSciences from a “neutral” rating to a “sell” rating and dropped their price objective for the stock from $7.00 to $4.25 in a research report on Thursday, December 5th. Baird R W downgraded Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Robert W. Baird cut Maravai LifeSciences from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $9.00 to $3.00 in a report on Wednesday, February 26th. Guggenheim initiated coverage on Maravai LifeSciences in a report on Thursday, December 19th. They set a “neutral” rating for the company. Finally, Bank of America reduced their target price on shares of Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $9.28.

Insider Buying and Selling at Maravai LifeSciences

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $5.03, for a total value of $125,750.00. Following the completion of the sale, the general counsel now owns 167,618 shares in the company, valued at approximately $843,118.54. This trade represents a 12.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.63% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Performa Ltd US LLC raised its holdings in Maravai LifeSciences by 614.3% in the fourth quarter. Performa Ltd US LLC now owns 5,000 shares of the company’s stock worth $27,000 after purchasing an additional 4,300 shares during the period. FNY Investment Advisers LLC increased its position in shares of Maravai LifeSciences by 600.0% in the 4th quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock valued at $38,000 after buying an additional 6,000 shares in the last quarter. Farther Finance Advisors LLC raised its stake in Maravai LifeSciences by 3,541.4% during the 4th quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company’s stock worth $56,000 after buying an additional 9,916 shares during the period. Cibc World Markets Corp bought a new position in Maravai LifeSciences during the fourth quarter worth about $56,000. Finally, Atria Investments Inc acquired a new position in Maravai LifeSciences in the fourth quarter valued at about $58,000. Institutional investors and hedge funds own 50.25% of the company’s stock.

Maravai LifeSciences Price Performance

Maravai LifeSciences stock opened at $2.40 on Friday. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. The firm has a market capitalization of $606.07 million, a P/E ratio of -1.46 and a beta of -0.08. The business has a 50-day moving average of $4.01 and a 200-day moving average of $5.88. Maravai LifeSciences has a 1 year low of $2.25 and a 1 year high of $11.56.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.